These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 32493331)

  • 1. An evidence mapping and analysis of registered COVID-19 clinical trials in China.
    Lu L; Li F; Wen H; Ge S; Zeng J; Luo W; Wang L; Tang C; Xu N
    BMC Med; 2020 Jun; 18(1):167. PubMed ID: 32493331
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Study Design Characteristics and Pharmacological Mechanisms in International Clinical Trials Registry Platform: Registered Clinical Trials on Antiviral Drugs for COVID-19.
    Zhang W; Lv Y; Yang J; Chen Y; He Y; Huang J
    Drug Des Devel Ther; 2020; 14():3803-3813. PubMed ID: 32982184
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characteristics of COVID-19 Clinical Trials in China Based on the Registration Data on ChiCTR and ClinicalTrials.gov.
    Huang J; He Y; Su Q; Yang J
    Drug Des Devel Ther; 2020; 14():2159-2164. PubMed ID: 32581514
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Research methodology and characteristics of journal articles with original data, preprint articles and registered clinical trial protocols about COVID-19.
    Fidahic M; Nujic D; Runjic R; Civljak M; Markotic F; Lovric Makaric Z; Puljak L
    BMC Med Res Methodol; 2020 Jun; 20(1):161. PubMed ID: 32571302
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Analysis on clinical study protocols of traditional Chinese medicine for coronavirus disease 2019].
    Wang H; Jin XY; Pang B; Liu CX; Zheng WK; Yang FW; Pang WT; Zhang JH
    Zhongguo Zhong Yao Za Zhi; 2020 Mar; 45(6):1232-1241. PubMed ID: 32281330
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Profiles of COVID-19 clinical trials in the Chinese Clinical Trial Registry.
    Xu P; Xing X; Yu K; Lv Z; Cui H; Shi Y; Chang T; Zhang D; Zhang Y; Wang K; Lu J; Huang Q; Li X; Cui Y; Shi L; Wang T; Niu J; Wang J
    Emerg Microbes Infect; 2020 Dec; 9(1):1695-1701. PubMed ID: 32615862
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A multi-center, randomized controlled trial by the Integrative Management in Japan for Epidemic Disease (IMJEDI study-RCT) on the use of Kampo medicine, kakkonto with shosaikotokakikyosekko, in mild-to-moderate COVID-19 patients for symptomatic relief and prevention of severe stage: a structured summary of a study protocol for a randomized controlled trial.
    Takayama S; Namiki T; Ito T; Arita R; Nakae H; Kobayashi S; Yoshino T; Ishigami T; Tanaka K; Kainuma M; Nochioka K; Takagi A; Mimura M; Yamaguchi T; Ishii T
    Trials; 2020 Oct; 21(1):827. PubMed ID: 33008479
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Review of trials currently testing treatment and prevention of COVID-19.
    Fragkou PC; Belhadi D; Peiffer-Smadja N; Moschopoulos CD; Lescure FX; Janocha H; Karofylakis E; Yazdanpanah Y; Mentré F; Skevaki C; Laouénan C; Tsiodras S;
    Clin Microbiol Infect; 2020 Aug; 26(8):988-998. PubMed ID: 32454187
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Phase 3 Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Intravenously Administered Ravulizumab Compared with Best Supportive Care in Patients with COVID-19 Severe Pneumonia, Acute Lung Injury, or Acute Respiratory Distress Syndrome: A structured summary of a study protocol for a randomised controlled trial.
    Smith K; Pace A; Ortiz S; Kazani S; Rottinghaus S
    Trials; 2020 Jul; 21(1):639. PubMed ID: 32660611
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systematic review of the registered clinical trials for coronavirus disease 2019 (COVID-19).
    Zhu RF; Gao YL; Robert SH; Gao JP; Yang SG; Zhu CT
    J Transl Med; 2020 Jul; 18(1):274. PubMed ID: 32631442
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Mechanism and Clinical Outcome of patients with Corona Virus Disease 2019 Whose Nucleic Acid Test has changed from negative to positive, and the therapeutic efficacy of Favipiravir: A structured summary of a study protocol for a randomised controlled trial.
    Li J; Zhang C; Wu Z; Wang G; Zhao H
    Trials; 2020 Jun; 21(1):488. PubMed ID: 32503657
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characteristics of registered clinical trials assessing treatments for COVID-19: a cross-sectional analysis.
    Mehta HB; Ehrhardt S; Moore TJ; Segal JB; Alexander GC
    BMJ Open; 2020 Jun; 10(6):e039978. PubMed ID: 32518212
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development and progress of clinical trials of Coronavirus Disease 2019 antiviral drugs.
    Pang W; Wang Q; Zhao Z
    Expert Rev Clin Pharmacol; 2020 Sep; 13(9):945-956. PubMed ID: 32729363
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chloroquine and its derivatives in the management of COVID-19: A scoping review.
    Pimentel J; Andersson N
    Biomedica; 2020 Oct; 40(Supl. 2):80-95. PubMed ID: 33152192
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The SARS-CoV-2 Ivermectin Navarra-ISGlobal Trial (SAINT) to Evaluate the Potential of Ivermectin to Reduce COVID-19 Transmission in low risk, non-severe COVID-19 patients in the first 48 hours after symptoms onset: A structured summary of a study protocol for a randomized control pilot trial.
    Chaccour C; Ruiz-Castillo P; Richardson MA; Moncunill G; Casellas A; Carmona-Torre F; Giráldez M; Mota JS; Yuste JR; Azanza JR; Fernández M; Reina G; Dobaño C; Brew J; Sadaba B; Hammann F; Rabinovich R
    Trials; 2020 Jun; 21(1):498. PubMed ID: 32513289
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of the efficacy and safety of intravenous remdesivir in adult patients with severe COVID-19: study protocol for a phase 3 randomized, double-blind, placebo-controlled, multicentre trial.
    Wang Y; Zhou F; Zhang D; Zhao J; Du R; Hu Y; Cheng Z; Gao L; Jin Y; Luo G; Fu S; Lu Q; Du G; Wang K; Lu Y; Fan G; Zhang Y; Liu Y; Ruan S; Liu W; Jaki T; Hayden FG; Horby PW; Cao B; Wang C
    Trials; 2020 May; 21(1):422. PubMed ID: 32448345
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of Lianhua Qingwen combined with conventional antiviral Western Medicine in the treatment of coronavirus disease (covid-19) in 2019: Protocol for a systematic review and meta-analysis.
    Zhang X; Cao D; Liu J; Zhang Q; Liu M
    Medicine (Baltimore); 2020 Jul; 99(30):e21404. PubMed ID: 32791754
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of the WHO ICTRP for novel coronavirus clinical trial registrations.
    Song G; Cheng MQ; Wei XW
    Medicine (Baltimore); 2020 Oct; 99(43):e22840. PubMed ID: 33120812
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of Anluohuaxian in the treatment of patients with severe Coronavirus disease 2019- a multicenter, open label, randomized controlled study: a structured summary of a study protocol for a randomised controlled trial.
    Zhang C; Li J; Wu Z; Wang H; Que C; Zhao H; Wang G
    Trials; 2020 Jun; 21(1):495. PubMed ID: 32513299
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.